EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access

Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL

Robin Foà iD, Renato Bassan iD, Loredana Elia, Alfonso Piciocchi iD, Stefano Soddu iD, Monica Messina iD, Felicetto Ferrara, Monia Lunghi, Antonino Mulè, Massimiliano Bonifacio, Nicola Fracchiolla iD, Prassede Salutari und 4 weitere

Journal of Clinical Oncology · 10.03.2024 · 42 (8) · 881-885

DOI: 10.1200/jco.23.01075 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.03.2024. Verfasst von Robin Foà und 15 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antibodies, Bispecific. Die Arbeit wurde bisher 168-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We report the long-term results of the frontline trial with dasatinib and blinatumomab in induction/consolidation (GIMEMA LAL2116, D-ALBA) for adult Philadelphia-positive ALL (Ph+ ALL), which enrolled 63 patients of all ages. At a median follow-up of 53 months, disease-free survival, overall survival, and event-free survival are 75.8%, 80.7%, and 74.6%, respectively. No events have occurred among early molecular responders. A significantly worse outcome was recorded for IKZF1 plus patients. Twenty-nine patients—93.1% being in molecular response (ie, complete molecular response or positive nonquantifiable) after dasatinib/blinatumomab—never received chemotherapy/transplant and continued with a tyrosine kinase inhibitor only; 28 patients remain in long-term complete hematologic response (CHR). An allogeneic transplant was carried out in first CHR mainly in patients with persistent minimal residual disease; 83.3% of patients are in continuous CHR. The transplant-related mortality was 12.5% for patients transplanted in first CHR and 13.7% overall. Nine relapses and six deaths have occurred. ABL1 mutations were found in seven cases. The final analysis of the D-ALBA study shows that a chemotherapy-free induction/consolidation regimen on the basis of a targeted strategy (dasatinib) and immunotherapy (blinatumomab) is effective in inducing durable long-term hematologic and molecular responses in adult Ph+ ALL, paving the way for a new era in the management of these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaAntibodies, BispecificAdultHumansDasatinibTreatment OutcomeNeoplasm Recurrence, Local

Substanzen

DasatinibblinatumomabAntibodies, Bispecific

Autor:innen und Institutionen

  • Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
  • Hematology Unit, Ospedale dell'Angelo and Ospedale Ss Giovanni e Paolo, Mestre Venezia, Italy.
  • GIMEMA Data Center, Fondazione GIMEMA Franco Mandelli Onlus, Rome, Italy.
  • Division of Hematology, Cardarelli Hospital, Naples, Italy.
  • Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
  • UOC Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy.

ORCID-Profile: Robin Foà, Renato Bassan, Alfonso Piciocchi, Stefano Soddu, Monica Messina, Nicola Fracchiolla, Paola Fazi, Anna Guarini, Alessandro Rambaldi, Sabina Chiaretti

Zitieren

APA

Foà, R., Bassan, R., Elia, L., Piciocchi, A., Soddu, S., Messina, M., Ferrara, F., Lunghi, M., Mulè, A., Bonifacio, M., Fracchiolla, N., Salutari, P., Fazi, P., Guarini, A., Rambaldi, A., & Chiaretti, S. (2024). Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL. Journal of Clinical Oncology, 42(8), 881-885. https://doi.org/10.1200/jco.23.01075

Vancouver

Foà R, Bassan R, Elia L, Piciocchi A, Soddu S, Messina M, et al. Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL. Journal of Clinical Oncology. 2024;42(8):881-885. doi:10.1200/jco.23.01075

BibTeX
@article{Fo2024,
  author = {Foà, Robin and Bassan, Renato and Elia, Loredana and Piciocchi, Alfonso and Soddu, Stefano and Messina, Monica and Ferrara, Felicetto and Lunghi, Monia and Mulè, Antonino and Bonifacio, Massimiliano and Fracchiolla, Nicola and Salutari, Prassede and Fazi, Paola and Guarini, Anna and Rambaldi, Alessandro and Chiaretti, Sabina},
  title = {Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {8},
  pages = {881--885},
  doi = {10.1200/jco.23.01075}
}
Kostenlos starten →